BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37109649)

  • 1. Evaluating the Nephrotoxicity of Area-under-the-Curve-Based Dosing of Vancomycin with Concomitant Antipseudomonal Beta-Lactam Antibiotics: A Systematic Review and Meta-Analysis.
    Chiu CY; Sarwal A
    Medicina (Kaunas); 2023 Mar; 59(4):. PubMed ID: 37109649
    [No Abstract]   [Full Text] [Related]  

  • 2. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
    Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
    Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
    J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Large-Scale Multicenter Retrospective Study on Nephrotoxicity Associated With Empiric Broad-Spectrum Antibiotics in Critically Ill Patients.
    Chen AY; Deng CY; Calvachi-Prieto P; Armengol de la Hoz MÁ; Khazi-Syed A; Chen C; Scurlock C; Becker CD; Johnson AEW; Celi LA; Dagan A
    Chest; 2023 Aug; 164(2):355-368. PubMed ID: 37040818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
    Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
    Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin.
    Lee JD; Heintz BH; Mosher HJ; Livorsi DJ; Egge JA; Lund BC
    Clin Infect Dis; 2021 Oct; 73(7):e1579-e1586. PubMed ID: 33382398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury.
    Muklewicz JD; Steuber TD; Edwards JD
    Int J Antimicrob Agents; 2021 Jan; 57(1):106234. PubMed ID: 33232734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
    Robertson AD; Li C; Hammond DA; Dickey TA
    Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem.
    Mefford B; Wallace KL; Donaldson JC; Bissell Turpin BD; Sen P; Schadler AD; Liu LJ; Thompson Bastin ML
    Antimicrob Agents Chemother; 2024 May; 68(5):e0108523. PubMed ID: 38606975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
    Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
    JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem.
    Rungkitwattanakul D; Ives AL; Harriott NG; Pan-Chen S; Duong L
    J Chemother; 2022 Apr; 34(2):103-109. PubMed ID: 34424136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
    Navalkele B; Pogue JM; Karino S; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Koons J; Hussain T; Perry W; Evans R; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Kaye KS
    Clin Infect Dis; 2017 Jan; 64(2):116-123. PubMed ID: 27986669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin.
    Schreier DJ; Kashani KB; Sakhuja A; Mara KC; Tootooni MS; Personett HA; Nelson S; Rule AD; Steckelberg JM; Tande AJ; Barreto EF
    Clin Infect Dis; 2019 Apr; 68(9):1456-1462. PubMed ID: 30165426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: A retrospective cohort study.
    O'Callaghan K; Hay K; Lavana J; McNamara JF
    Int J Antimicrob Agents; 2020 Jul; 56(1):106010. PubMed ID: 32413387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin With Concomitant Piperacillin/Tazobactam vs. Cefepime or Meropenem Associated Acute Kidney Injury in General Ward Patients: A Multicenter Propensity Score-Matched Study.
    Komerdelj IA; Buckley MS; D'Alessio PA; Ziadat DS; Kobic E; Rangan P; Agarwal SK; Tinta NC; Yerondopoulos MJ; Kane-Gill SL
    J Pharm Pract; 2024 Feb; 37(1):80-87. PubMed ID: 36075000
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study.
    Okada N; Izumi Y; Nakamoto A; Chuma M; Goda M; Yagi K; Aizawa F; Hamano H; Zamami Y; Azuma M; Ishizawa K
    Clin Ther; 2021 Nov; 43(11):1910-1920.e3. PubMed ID: 34642081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute kidney injury following the concurrent administration of antipseudomonal β-lactams and vancomycin: a network meta-analysis.
    Bellos I; Karageorgiou V; Pergialiotis V; Perrea DN
    Clin Microbiol Infect; 2020 Jun; 26(6):696-705. PubMed ID: 32222460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients.
    Buhlinger KM; Fuller KA; Faircloth CB; Wallace JR
    Am J Health Syst Pharm; 2019 Aug; 76(16):1204-1210. PubMed ID: 31369115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of combining vancomycin with piperacillin/tazobactam or with meropenem on vancomycin-induced nephrotoxicity.
    Tookhi RF; Kabli NA; Huntul MA; Thabit AK
    Intern Emerg Med; 2021 Jun; 16(4):975-979. PubMed ID: 33439417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.